@oliolabs.bsky.social
Reposted
Some really cool work we've been doing @oliolabs.bsky.social. New science opens the door to better medicines.
Sex differences in GLP-1 signaling across species https://www.biorxiv.org/content/10.1101/2025.03.17.643822v1
March 19, 2025 at 10:16 PM
Some really cool work we've been doing @oliolabs.bsky.social. New science opens the door to better medicines.
Check out what we're working on at Olio Labs!
70% of patients taking GLP-1's (like Ozempic) are women, but they experience >2x side effect rates than men.
What is driving this difference?
We combine human EMR data, mouse & rat behavior, and scRNAseq to figure it out:
70% of patients taking GLP-1's (like Ozempic) are women, but they experience >2x side effect rates than men.
What is driving this difference?
We combine human EMR data, mouse & rat behavior, and scRNAseq to figure it out:
March 19, 2025 at 7:27 PM
Check out what we're working on at Olio Labs!
70% of patients taking GLP-1's (like Ozempic) are women, but they experience >2x side effect rates than men.
What is driving this difference?
We combine human EMR data, mouse & rat behavior, and scRNAseq to figure it out:
70% of patients taking GLP-1's (like Ozempic) are women, but they experience >2x side effect rates than men.
What is driving this difference?
We combine human EMR data, mouse & rat behavior, and scRNAseq to figure it out: